EDF vs MelApp

This guideline has been developed by and for doctors involved in the treatment of psoriasis. The recommendations for the different treatment options are rated according to their strength. The guideline offers advice on patient monitoring, contraindications and adverse events. Recommendations are also made for groups of patients who require special consideration when receiving psoriasis treatment, such as those with a history of malingnacy, HIV infection or impaired liver or kidney function. The guideline has originally been published in the Journal of the European Academy of Dermatology and Venereology (JEADV) by Nast A, et al. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94. doi: 10.1111/jdv.13354

Identify rapidly and accurately T, N, M parameters for melanoma staging, guiding you through the complex AJCC tables. Correct staging of melanoma is of fundamental importance for the correct treatment of patients suffering from this condition. In 2018, the eighth edition of the American Joint Committee on Cancer (AJCC) T-N-M classification came into effect to improve the prognostic stratification of melanoma. Calculating the stage of melanoma may not be easy. MelApp is a supporting app that helps you navigate quickly and accurately through the complex AJCC tables. By simply selecting items from a drop-down menu, set according to the criteria of the AJCC tables, MelApp also allows you to identify the three T-N-M parameters. By cross-referencing the three values thus obtained, the final result, parameter S, will help you determine the stage of the lesion as identified by the AJCC tables and suggest possible follow-up indications. MelApp is developed by Meeter Congressi in collaboration with Melanoma Unit - University of Campania "Luigi Vanvitelli", Prof. Giuseppe Argenziano, Dr. Elvira Moscarella, Dr. Gabriella Brancaccio and Dr. Teresa Russo. Meeter Congressi and Melanoma Unit have developed MelApp based on the information contained in the AJCC Cancer Staging Manual. The definitions used are copyrighted by AJCC. We are not responsible for the academic accuracy or thoroughness of the information contained in the AJCC Cancer Staging Manual. Meeter Congressi and Melanoma Unit shall not be held liable for any damages arising out of the use of the information contained in MelApp, for any injury or damage to persons or property resulting from the use of the app or any of its features, including lost profits, punitive or exemplary damages, since it serves only as guidance support for the AJCC tables. MelApp is an entertainment tool for health care worker education and is not a diagnostic and therapeutic resource. MelApp is not a medical device. MelApp should not be used for the diagnosis or treatment of melanoma. Only a doctor can diagnose or treat melanoma. Possible follow-up indications are for guidance only. Only a doctor can diagnose or treat melanoma. MelApp is not intended to replace the results of the patient's medical history and objective examination.